Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , March 27, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL), one of the world's leading pharmaceutical companies, and Biocon Ltd. (BSE code: 532523, NSE: BIOCON ), Asia's premier biopharmaceutical company, today announced that their
View HTML
Toggle Summary Mylan to Host Investor Day on April 11, 2018, in New York City
HERTFORDSHIRE, England and PITTSBURGH , March 21, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced that it will host an Investor Day on April 11, 2018 , in New York City . Mylan CEO Heather Bresch and the company's senior leadership team will showcase how Mylan is Built to Last
View HTML
Toggle Summary Mylan Adds to Growing Oncology Portfolio with Launch of Generic Mutamycin® Injection
- Mitomycin for Injection is available to Mylan's hospital and other institutional customers - HERTFORDSHIRE, England and PITTSBURGH , March 20, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ:MYL) today announced the U.S. launch of the oncology drug Mitomycin for Injection
View HTML
Toggle Summary Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
- FDA recently approved Symfi Lo™, a three-drug single-tablet antiretroviral (ARV) regimen, and Cimduo™, a double combination, for HIV treatment - Mylan will launch Symfi Lo and Cimduo at a significant discount to the price of competing products to bring cost savings to the $20 billion U.S.
View HTML
Toggle Summary Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance
HERTFORDSHIRE , England and PITTSBURGH , Feb. 28, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the year ended December 31, 2017 and Fourth Quarter 2017 and provided 2018 guidance. Full Year 2017 Financial Highlights Total revenues of $11.91 billion , up 8%
View HTML
Toggle Summary Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
HERTFORDSHIRE, England and PITTSBURGH , and NEWARK, Calif. , Feb. 28, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX
View HTML
Toggle Summary Mylan to Present at Raymond James 39th Annual Institutional Investors Conference
HERTFORDSHIRE, England and PITTSBURGH , Feb. 28, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced that its CFO, Ken Parks , will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Fla. , on Monday, Mar. 5, 2018 , at 1:40 p.m. ET .
View HTML
Toggle Summary Mylan to Present at Barclays Global Healthcare Conference
HERTFORDSHIRE, England and PITTSBURGH , Feb. 28, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced that its CEO, Heather Bresch , will present at the Barclays Global Healthcare Conference in Miami Beach, Fla. , on Wednesday, Mar. 14, 2018 , at 3:20 p.m. ET .
View HTML
Toggle Summary Mylan Defeats Allergan's Maneuver to Rent Tribal Sovereign Immunity to Avoid Restasis® Patent Challenge
U.S. Patent Trial and Appeal Board denies St. Regis Mohawk Tribe's motion to terminate Restasis patent challenge Decision finds that Tribal sovereign immunity does not apply to inter partes review proceedings Federal District Court previously held patents invalid HERTFORDSHIRE, England
View HTML
Toggle Summary 16-Year Veteran Director Wendy Cameron to Retire from Mylan N.V. Board after 2018 AGM
Mylan Board Nominates Pauline van der Meer Mohr for Election to Board of Directors HERTFORDSHIRE, England and PITTSBURGH , Feb. 26, 2018 /PRNewswire/ -- The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced that non-executive Director Wendy Cameron will retire from the Board after more
View HTML